(PDF) Emerging Drugs and Targets for Parkinson’s Disease by Ana Martinez

This is the PDF eBook version for Emerging Drugs and Targets for Parkinson’s Disease by Ana Martinez, Carmen Gil, Jose Lopez-Barneo, Pablo Martinez-Martin, Laszlo Vecsei

Table of Contents

Overview on Parkinson disease. Rational for pharmacological intervention; Dopaminergic pathway and L-Dopa treatments. Future challenges; COMT Inhibitors: present problems and relevance of the new ones; MAO inhibitors for PD (Safinamide); Dopamine agonist: present and future (Pardoprunox); Therapies for dopaminergic-induced dyskinesias in Parkinson disease. (Fipamizole); Beyond the dopamine receptor: regulation of protein phosphatases; Molecular chaperones as rational drug targets for Parkinson’s disease therapeutics; Alpha-synuclein assembly as a therapeutic target of PD; Alpha-synuclein (alpha-syn) phosphorylating polo-like kinase 2 (PLK2) as target for PD; Hsp70 molecular chaperones and Parkinson’s disease; Glutamate receptors as therapeutic targets for Parkinson’s disease; Targeting adenosine A2A receptors in Parkinson’s disease; Leucine-rich repeat kinase-2 as target for Parkinson’s disease; Phosphodiesterase inhibitors for PD treatment; P2X7 purinergic receptor: role in neurological disorders; Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson’s disease; D3 dopamine receptor agonists: neuroprotection in Parkinson’s disease; Antioxidants and PD; Tryptophan metabolism in Parkinson’s disease; Grafted neural stem cell-derived dopaminergic neurons for PD Therapy; Gene therapy for Parkinson’s disease; Carotid body autotransplantation in Parkinson disease;Neurotrophic factor therapy for Parkinson’s disease